Table 1.
Baseline Characteristics
| No Primary Endpoint (n=190) | Primary Endpoint (n=45) | p-value | |
|---|---|---|---|
| Male (%) | 143 (75) | 36 (80) | 0.50 |
| Age (mean±SD) (years) | 57±13 | 60±10 | 0.23 |
| Caucasian/African-American/Other (%) | 135 (71)/48 (25)/6 (3) | 30 (67)/14 (31)/1 (2) | 0.71 |
| Ischemic etiology (%) | 110 (58) | 27 (60) | 0.80 |
| Years from incident MI/cardiomyopathy diagnosis (median) | 2.2 [IQR 0.5–7.4] | 5.7 [0.7–12.3] | 0.09 |
| NYHA Class I/ II/ III (%) | 48 (25)/77 (41)/65 (34) | 9 (20)/19 (42)/17 (38) | 0.75 |
| Risk factors (%) | |||
| Hypertension | 109 (57) | 26 (58) | 0.96 |
| Hypercholesterolemia | 112 (59) | 29 (64) | 0.50 |
| Diabetes | 46 (24) | 14 (31) | 0.34 |
| Nicotine use | 95 (50) | 30 (67) | 0.04 |
| Medication usage (%) | |||
| ACE-inhibitor or ARB | 167 (88) | 41 (91) | 0.54 |
| Beta-blocker | 180 (95) | 40 (89) | 0.15 |
| Lipid-lowering | 132 (69) | 32 (71) | 0.83 |
| Antiarrhythmics (amio) | 11 (6) | 6 (13) | 0.08 |
| Diuretics | 101 (53) | 37 (82) | <0.001 |
| Digoxin | 35 (18) | 13 (29) | 0.12 |
| Aldosterone inhibitor | 37 (19) | 13 (29) | 0.17 |
| Aspirin | 140 (74) | 33 (73) | 0.96 |
| Electrophysiologic variables | |||
| Prior atrial fibrillation (%) | 33 (17) | 9 (20) | 0.68 |
| Heart rate | 71±13 bpm | 72±14 bpm | 0.55 |
| QRS duration | 119±30 msec | 122±29 msec | 0.57 |
| LBBB | 47 (25) | 7 (16) | 0.19 |
| Biventricular ICD | 53 (29) | 10 (22) | 0.35 |
| Laboratory/biomarker variables | |||
| Sodium (mEq/L) | 139±3 | 139±3 | 0.60 |
| Potassium (mEq/L) | 4.3±0.4 | 4.2±0.4 | 0.42 |
| Creatinine (mg/dL) | 1.03±0.5 | 1.06±0.3 | 0.73 |
| hsCRP (median, mg/L) | 2.7 [IQR 1.0–6.7] | 5.4 [IQR 2.8–13.3] | 0.001 |
| NT-proBNP (median, pg/ml) | 2095 [IQR 1400–3350] | 2520 [IQR 2080–4260] | 0.005 |
| Enrollment LVEF (non-CMR) | 23±7% | 22±8% | 0.29 |
| CMR characteristics | |||
| LVEF (mean±SD) | 27±9% | 24±10% | 0.05 |
| % with LVEF≤20% | 40 (21) | 17 (38) | 0.02 |
| LV end-diastolic volume index (ml/m2) | 123±37 | 139±61 | 0.03 |
| LV end-systolic volume index (ml/m2) | 91±36 | 108±58 | 0.01 |
| LV mass index (ml/m2) | 82±26 | 88±41 | 0.25 |
| Hyperenhancement | |||
| LGE present (%) | 131 (69) | 40 (89) | 0.007 |
| Gray zone (median, grams) | 5.5 [IQR 0–15.3] | 13.3 [IQR 3.4–22.5] | 0.003 |
| Core (median, grams) | 10.6 [IQR 0–21.4] | 15.8 [IQR 4.3–22.8] | 0.06 |
| Total (median, grams) | 17.1 [IQR 0–38.9] | 32.7 [IQR 7.3–46.7] | 0.02 |